Ouyang Yonghao, Liu Pengpeng, Chu Lihua, Xiao Yi, Zhu Hong, Zhang Caihua
Research Institute of General Surgery, Jinling Hospital, Nanjing 210000, China.
Department of Hepatobiliary, Xuzhou Central Hospital, Xuzhou 221000, China.
Heliyon. 2024 Sep 26;10(19):e38430. doi: 10.1016/j.heliyon.2024.e38430. eCollection 2024 Oct 15.
Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy.
117 patients with invasive IPMC were included in The Surveillance, Epidemiology, and End Results (SEER) database. These patients were subsequently divided into two subgroups according to whether they received chemotherapy or not: the non-chemotherapy group (patients who did not receivechemotherapy, N = 58), the chemotherapy group (patients who received chemotherapy, N = 59). The overall survival (OS) and cancer specific survival (CSS) of two treatment groups were evaluated.
Before adjusting for pathology grade, the Kaplan-Meier analysis showed that the difference of survival time is not significant between non-chemotherapy group and chemotherapy group (P > 0.05), but the land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group (P < 0.05). After adjust the pathology grade, survival time of the chemotherapy group is significantly longer than non-chemotherapy group (P < 0.05). Univariate and multivariate Cox regression showed that chemotherapy was an independent prognostic protective factor for invasive IPMC (P < 0.05). Land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group in N1-N2 subgroup (P < 0.05).
Chemotherapy is an independent protective factor IPMC, especially reducing the risk of short-term death for IPMC patients with lymph node metastasis.
化疗能否改善浸润性导管内乳头状黏液性癌（IPMC）的预后仍不清楚。本研究的目的是观察接受或未接受化疗的浸润性IPMC患者生存时间的差异。
117例浸润性IPMC患者纳入监测、流行病学和最终结果（SEER）数据库。这些患者随后根据是否接受化疗分为两个亚组：非化疗组（未接受化疗的患者，N = 58），化疗组（接受化疗的患者，N = 59）。评估两个治疗组的总生存期（OS）和癌症特异性生存期（CSS）。
在调整病理分级之前，Kaplan-Meier分析显示非化疗组和化疗组之间生存时间差异不显著（P>0.05），但地标分析显示化疗组的短期死亡风险显著低于非化疗组（P<0.05）。调整病理分级后，化疗组的生存时间显著长于非化疗组（P<0.05）。单因素和多因素Cox回归显示化疗是浸润性IPMC的独立预后保护因素（P<0.05）。地标分析显示，在N1-N2亚组中，化疗组的短期死亡风险显著低于非化疗组（P<0.05）。
化疗是IPMC的独立保护因素，尤其是降低有淋巴结转移的IPMC患者的短期死亡风险。
